AZD4320

dual inhibitor of Bcl-2 and Bcl-x L

Also Known As:

4-(4-((R)-(2-(4-chlorophenyl)phenyl)-hydroxymethyl)piperidin-1-yl)-N-(4-(((2R)-4-(2-hydroxyethyl(methyl)amino)-1-phenylsulfanylbutan-2-yl)amino)-3-(trifluoromethylsulfonyl)phenyl)sulfonylbenzamide

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Balachander, Srividya B: 2 articles (05/2021 - 12/2020)
2.	Arulananda, Surein: 1 article (05/2021)
3.	Cebon, Jonathan: 1 article (05/2021)
4.	Cidado, Justin R: 1 article (05/2021)
5.	Evangelista, Marco: 1 article (05/2021)
6.	Fairlie, Walter D: 1 article (05/2021)
7.	Jenkins, Laura J: 1 article (05/2021)
8.	John, Thomas: 1 article (05/2021)
9.	Lee, Erinna F: 1 article (05/2021)
10.	Leong, Trishe: 1 article (05/2021)

Related Diseases

1.	Neoplasms (Cancer) 12/15/2020 - "A single intravenous bolus dose of AZD4320 induces tumor regression with transient thrombocytopenia, which recovers in less than a week, suggesting a clinical weekly schedule would enable targeting of Bcl-2/Bcl-xL-dependent tumors without incurring dose-limiting thrombocytopenia. " 12/15/2020 - "AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia." 05/28/2021 - "In this study we show another inhibitor, AZD4320 that targets BCL-XL (and BCL-2), can also potently kill MPM tumor cells in vitro (EC50 values in the 200 nM range) and this effect is enhanced by co-inhibition of MCL-1 using AZD5991. " 12/15/2020 - "AZD4320 is a potent molecule with manageable thrombocytopenia risk to explore the utility of a dual Bcl-2/Bcl-xL inhibitor across a broad range of tumor types with dysregulation of Bcl-2 prosurvival proteins." 12/15/2020 - "AZD4320 demonstrates activity in both Bcl-2- and Bcl-xL-dependent hematologic cancer cell lines and enhanced activity in acute myeloid leukemia (AML) patient samples compared with the Bcl-2-selective agent venetoclax. "
2.	B-Cell Lymphoma (Lymphoma, B Cell) 01/01/2019 - "Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2."
3.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/15/2020 - "AZD4320 demonstrates activity in both Bcl-2- and Bcl-xL-dependent hematologic cancer cell lines and enhanced activity in acute myeloid leukemia (AML) patient samples compared with the Bcl-2-selective agent venetoclax. "
4.	Thrombocytopenia (Thrombopenia) 12/15/2020 - "A single intravenous bolus dose of AZD4320 induces tumor regression with transient thrombocytopenia, which recovers in less than a week, suggesting a clinical weekly schedule would enable targeting of Bcl-2/Bcl-xL-dependent tumors without incurring dose-limiting thrombocytopenia. " 12/15/2020 - "AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia." 12/15/2020 - "AZD4320 is a potent molecule with manageable thrombocytopenia risk to explore the utility of a dual Bcl-2/Bcl-xL inhibitor across a broad range of tumor types with dysregulation of Bcl-2 prosurvival proteins."

Related Drugs and Biologics

1.	Dendrimers (Dendrons)
2.	Lysine (L-Lysine)
3.	Cisplatin (Platino)
4.	AZD0466
5.	AZD5991
6.	Proteins (Proteins, Gene)
7.	venetoclax
8.	AZD5153

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)